Hematology
Conference Coverage
Whole-genome sequencing demonstrates clinical relevance
GLASGOW – A study comparing whole-genome sequencing (WGS) with fluorescence in situ hybridization showed that the WGS was reliable and clinically...
Conference Coverage
Myeloma therapies raise cardiovascular risks
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous...
News
Barriers to CAR T use in the spotlight at first European meeting
European approvals of CAR T-cell therapy are prompting a closer look at economic issues, outcomes data, and future directions.
Conference Coverage
Biomarkers predict VTE risk with menopausal oral hormone therapy
CHICAGO – Pretreatment high D-dimer spells 500% increased VTE risk on oral hormone therapy.
FDA/CDC
Sickle cell infusion gains FDA breakthrough designation
The investigational therapy is aimed at preventing vasoocclusive crises.
News
Poor-prognosis cancers linked to highest suicide risk in first year
Pancreatic and lung cancer patients had high rates of suicide in comparison to the general population, while breast and prostate cancer patients...
Conference Coverage
Phase 3 data support apixaban for cancer-associated VTE
The rate of major bleeding was similar with apixaban and dalteparin.
Conference Coverage
NCI director: Data failures cost lives
SAN DIEGO – Too many patients die because numbers aren’t aggregated or shared, Dr. Ned Sharpless said at the ASH meeting.
Conference Coverage
2018: A banner year for hematology drug approvals
SAN DIEGO – There have been 32 new hematology drug approvals and the year isn’t over yet.
Video
Gut bacteria influence HCT outcomes
SAN DIEGO – Gut microbiome diversity predicts overall survival after hematopoietic cell transplant.